For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Cohort 1: CCH-aaes | CCH-aaes was administered to both buttocks without mitigation treatment (control group). | 0 | None | 0 | 7 | 6 | 7 | View |
| Cohort 2: CCH-aaes + Compression Garment | CCH-aaes was administered to both buttocks with compression garments as the mitigation treatment. | 0 | None | 0 | 8 | 8 | 8 | View |
| Cohort 3:CCH-aaes + Instant Cold Packs | CCH-aaes was administered to both buttocks with instant cold packs applied to the right buttock only for 5-10 minutes post injection as the mitigation treatment. | 0 | None | 0 | 9 | 9 | 9 | View |
| Cohort 4: CCH-aaes + Arnica Gel Patches (OcuMend) | CCH-aaes was administered to both buttocks with arnica gel patches (OcuMend) applied to the right buttock only immediately after injection and BID for 2 days as the mitigation treatment. | 0 | None | 0 | 9 | 9 | 9 | View |
| Cohort 5: CCH-aaes + INhance Post-Injection Serum With TriHex Technology® | CCH-aaes was administered to both buttocks with INhance Post-Injection Serum with TriHex Technology® applied to the right buttock only QID for up to 7 days as the mitigation treatment. | 0 | None | 0 | 8 | 8 | 8 | View |
| Cohort 6: CCH-aaes + PDL | CCH-aaes was administered to both buttocks with PDL applied once to the right buttock only between Days 1-7 post injection as the mitigation treatment. | 0 | None | 0 | 7 | 6 | 7 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Injection site bruising | SYSTEMATIC_ASSESSMENT | General disorders | MedDRA 22.1 | View |
| Injection site discolouration | SYSTEMATIC_ASSESSMENT | General disorders | MedDRA 22.1 | View |
| Injection site nodule | SYSTEMATIC_ASSESSMENT | General disorders | MedDRA 22.1 | View |
| Injection site pain | SYSTEMATIC_ASSESSMENT | General disorders | MedDRA 22.1 | View |
| Injection site pruritus | SYSTEMATIC_ASSESSMENT | General disorders | MedDRA 22.1 | View |
| Contusion | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | MedDRA 22.1 | View |